Please login to the form below

Not currently logged in
Email:
Password:

Pfizer enters late-stage haemophilia B gene therapy trial

Race is on to free patients of regular injections

Pfizer has begun testing investigational gene therapy fidanacogene elaparvovec for the treatment of haemophilia B, triggering a race against Dutch biotech UniQure.

Pfizer

Pfizer’s phase III programme will test the Spark Therapeutics-developed compound after it gathers safety and efficacy data of current factor IX prophylaxis replacement therapy as a lead-in study.

This data will then serve as the within-subject control group for patients that enrol into the next part of the study.

Previous data has shown promise for the pharma giant, with results from an earlier phase I/II trial reporting that just one out of 15 patients experienced a bleed four weeks after treatment, showing ‘immense promise for the use of this potential one-time treatment option’.

Katherine High, president and head of research and development, Spark Therapeutics, said: “The initiation of the Phase III programme marks an important milestone toward our goal of one day potentially eliminating spontaneous bleeding.”

If all goes well for Pfizer, its therapy might free patients of regularly injecting an engineered version of clotting factor IX – which people with haemophilia B lack – as fidanacogene elaparvovec could allow patients to produce their own factor IX once treated.

Brenda Cooperstone, senior vice president and chief development officer, rare disease, Pfizer Global Product Development, said: “With the lead-in study now open and actively recruiting patients, we are excited to begin our Phase 3 programme evaluating fidanacogene elaparvovec for the treatment of hemophilia B.

“We look forward to the opportunity to continue the progress achieved by Spark Therapeutics for patients living with hemophilia B.”

The news of the phase III programme comes hot on the heels of UniQure’s haemophilia B gene therapy trial, which last month enrolled its first patient for its candidate AMT-061.

Now the race is on to potentially disrupt a multibillion-dollar market, but who will come out on top remains to be seen.

Article by
Gemma Jones

17th July 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics